The White House has pulled Dr. Heidi Overton's nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday night, one day before the Senate committee was set to vote.
The administration's message is plain, and so is its reason. A senior administration official told Axios, which first reported the decision, that Overton "lacks the support on the Hill to move forward with her confirmation." The count behind that message: the Senate Health, Education, Labor and Pensions Committee is split 12 Republicans to 11 Democrats. No Democrat was going to vote for her. Two Republicans she needed, Susan Collins of Maine and Lisa Murkowski of Alaska, would not say how they would vote. On that count, one defection ends the nomination, and the White House does not send a nominee up to be defeated when the votes are not there.
The committee's chairman, Sen. Bill Cassidy of Louisiana, gave a different account late Tuesday. He said Overton had the votes to pass the committee and the full Senate, and that the nomination fell over abortion: pro-life senators sought final assurances from the administration on life issues. "Tonight, the White House abandoned a viable confirmation path for Dr. Overton," Cassidy wrote on X. "The Administration withdrew Dr. Overton rather than make such commitments." Cassidy's break with the White House is public and sharp — and it comes from a senator who lost his primary in June and has weeks left in office.
"Tonight, the White House abandoned a viable confirmation path for Dr. Overton."
What neither side disputes is the wall Overton faced from every direction at once. Cassidy himself had called her support for the president's plan to break up combination vaccines "almost disqualifying" and pressed her hard at her September hearing. Anti-abortion groups were pressing over the FDA's safety review of the abortion pill mifepristone, which reports by March. And leaders of the Make America Healthy Again movement campaigned openly against her, saying she had blocked their policies inside the government. A nominee carrying the chairman's doubts, the pro-life fight and the MAHA fight at the same time had no clean path — and the administration chose to end it on its own timing rather than lose the vote in public.
The FDA has had no confirmed commissioner since Dr. Marty Makary resigned in May. It stays under acting commissioner Kyle Diamantas, and the agency has lost about a fifth of its staff since Trump took office. Cassidy closed his post with the cost of the delay: with Democrats taking the Senate in January, "confirming a permanent FDA Commissioner will fall to Senate Democrats." That is now the administration's task — to name a replacement who can get through while Republicans still hold the chamber. Sen. Roger Marshall of Kansas is being discussed. No new nominee has been announced.